Kite Pharma Overview
Company Headquarters: California, US
Founded: 2009
Company Working:
Kite Pharma, a clinical-stage biopharmaceutical company that is focused on the development and commercialization of novel cancer immunotherapy products. The company has been developing a pipeline of engineered, autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a CAR-based therapy is in Phase II of clinical trials. KTE-C19 is likely to aid in the treatment of patients with relapsed or refractory aggressive diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma. The company has one operating segment, which primarily focuses on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. The company operates as a cell therapy subsidiary of Gilead Sciences, Inc.
Strategy
Kite Pharma focuses on expanding its market in developing and underdeveloped regions by launching CAR T therapy products. Apart from this, the company is involved in developing innovative products for the treatment of cancer. Moreover, it is actively involved in strategic collaborations to increase its market penetration. The company also focuses on research to expand its product portfolio
